Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded

“We are pleased to see an exceptional quarter for DAYBUE, with very strong sales volume growth reflecting the early success of STIX in the US, as well as achievement of the positive CHMP opinion – both important steps toward bringing trofinetide to more patients with Rett syndrome globally. Subject to approval being confirmed, we now look forward to Acadia’s anticipated European launch later this year.” - Jon Pilcher, CEO of Neuren